Next Article in Journal
Isoflurane Rescue Schizophrenia-Related Deficits through Parvalbumin-Positive Neurons in the Dentate Gyrus
Next Article in Special Issue
How to Manage a Patient with Ocular Metastases?
Previous Article in Journal
Is It All about Endothelial Dysfunction? Focusing on the Alteration in Endothelial Integrity as a Key Determinant of Different Pathological Mechanisms
Previous Article in Special Issue
Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 10
Issue 11
10.3390/biomedicines10112758
Review Report
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab

Biomedicines 2022, 10(11), 2758; https://doi.org/10.3390/biomedicines10112758
by Félix Pham 1,2,*, Samy Belkaid 1,2, Denis Maillet 2,3, Cyrille B. Confavreux 2,4,5, Stéphane Dalle 1,2 and Julien Péron 2,3
Reviewer 1: Anonymous
Reviewer 2:
Prem Yadav
Biomedicines 2022, 10(11), 2758; https://doi.org/10.3390/biomedicines10112758
Submission received: 11 October 2022 / Revised: 25 October 2022 / Accepted: 26 October 2022 / Published: 31 October 2022
(This article belongs to the Special Issue Advances in Immunotherapy and Radiation Therapy for Cancer)

Round 1

Reviewer 1 Report

 

Overall, the manuscript is well written, scientifically interesting and logically structured presenting interesting information and novelties with certain statistical limitations.

However, they need to clarify some points.

The number of sample size is low so it seems to be very questionable to make strong enough estimates.

 

In addition, the authors have not compared survival/progression free survival data from patients with bone metastasis treated with standard therapy with a group of patients treated with standard therapy plus ipilimumab treatment. 

Before accepting the manuscript these clarifications are needed.

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The study by Pham et al. describes the impact of bone metastases on patients with renal cell carcinoma or melanoma treated with combo therapy ipilimumab plus nivolumab. The authors enrolled the patients in the single-center study. Furthermore, they have retrospectively collected clinical and biological data before initiating ipilimumab plus nivolumab to study the impact of baseline bone metastases on overall and progression-free survival of patients with advanced renal cell carcinoma or melanoma.

Overall, this is a sound study where results are well supported with good data. However, minor issues should be addressed to improve the manuscript's acceptability for publication.

 

Comments:

 

1.     What known biomarkers can be used to estimate the risk or benefits of this combined therapy?

 

2. The authors have mentioned this study's limitations, such as small sample size, single center based, etc. It would be informative to highlight the critical points like "how this study overcomes the limitations of the existing studies. For example, https://www.annalsofoncology.org/article/S0923-7534(22)00083-7/pdf

 

3. What could be the possible way to overcome these limitations in the future should be included in the concluding sections of the discussion as PERSPECTIVE.

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop